Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Organon Pharma Focus Is "Short Term": Strategic Decisions Later

This article was originally published in The Pink Sheet Daily

Executive Summary

Akzo Nobel wants to "fix pharma first" before it makes any decisions about long-term strategy in Rx sector, company says. Sales of Follistim are being held back by supply problems following shutdown of West Orange, N.J. plant.
Advertisement

Related Content

Organon Zemuron Shortage Continues
Biotech Manufacturing May Be Key To R&D Deals, Organon Says
Biotech Manufacturing May Be Key To R&D Deals, Organon Says
Organon To Open Cambridge, Mass. R&D Facility In Early 2005
Organon To Open Cambridge, Mass. R&D Facility In Early 2005
Organon Abandons Gepirone Following Second “Not Approvable” Letter
Akzo Nobel Pharma In For “Rough Ride” In 2004; Firm Will Rely On Partnering, R&D Investment
Akzo Nobel Pharma In For “Rough Ride” In 2004; Firm Will Rely On Partnering, R&D Investment
Organon Building New Quality Affairs Group; New Jersey Plant To Close

Topics

Advertisement
UsernamePublicRestriction

Register

PS060033

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel